Viridian Metals Inc

Serge Belanger maintains a Buy rating on Viridian Therapeutics (VRDN) with a $38 price target, citing lonigutamab's lower efficacy compared to VRDN-001 in phase 1/2 trials and VRDN-001's potential for more effective treatment options as key factors.

Viridian Therapeutics announced positive THRIVE-2 phase 3 trial results for VRDN-001 (veligrotug), an anti-IGF-1R antibody for chronic thyroid eye disease (TED). The trial met all primary and secondary endpoints, showing significant improvements in proptosis, clinical activity score (CAS), and diplopia. Veligrotug was well-tolerated and showed a low rate of hearing impairment. The company plans to advance VRDN-003 into phase 3 trials and expects topline data in 2026.

Viridian Therapeutics' stock surged after its Phase III trial of veligrotug met all endpoints, showing a 56% proptosis responder rate and a 2.34mm mean reduction in proptosis in chronic thyroid eye disease patients. The treatment also achieved a 56% diplopia response rate, with 32% complete resolution, compared to 14% in placebo patients.

Veligrotug met all primary and secondary endpoints in THRIVE-2, showing 56% proptosis and diplopia responder rates, and 32% diplopia complete resolution. It was well-tolerated with 94% treatment completion and a 9.6% placebo-adjusted hearing impairment rate. BLA submission planned for 2025, with VRDN-003 trials on track for 2026 data.

Viridian Therapeutics' THRIVE-2 phase 3 trial of veligrotug for chronic thyroid eye disease met all endpoints, showing significant improvements in symptoms like proptosis, CAS, and diplopia. 56% of veligrotug patients responded positively, with rapid onset observed. Veligrotug was well-tolerated, supporting its potential as a best-in-class treatment.

A mother raises funds for gene therapy for her son's rare disease, offering to name the treatment after the highest donor. Edgewise Therapeutics' experimental drug for Duchenne muscular dystrophy shows positive results. Neurocrine Biosciences gains FDA approval for a congenital adrenal hyperplasia drug. AbbVie acquires Nimble Therapeutics for $200 million. Viridian Therapeutics' drug improves thyroid eye disease symptoms. Novo Holdings' acquisition of Catalent is finalized. South African regulators end investigation into Vertex's cystic fibrosis drug Trikafta.

Viridian Therapeutics reports positive THRIVE-2 phase 3 trial results for veligrotug, an intravenous treatment for chronic thyroid eye disease (TED), meeting all endpoints. Veligrotug showed a 56% proptosis and diplopia responder rate, with a 48% placebo-adjusted proptosis responder rate. The treatment was well-tolerated, with 94% of patients completing the course. Viridian anticipates a Biologics License Application (BLA) submission in 2025 and is advancing VRDN-003, a subcutaneous anti-IGF-1R antibody. The company remains financially strong, with a cash reserve of $753 million as of September 30, 2024, expected to fund operations into 2027. Analysts maintain an optimistic outlook on Viridian's stock.

Viridian Therapeutics to report THRIVE-2 phase 3 trial data on veligrotug for chronic thyroid eye disease on Dec 16, 2024. Conference call at 8:00am ET.

Viridian Therapeutics announced positive Phase 3 THRIVE-2 trial results for veligrotug in chronic thyroid eye disease, showing significant efficacy in proptosis and diplopia with a favorable safety profile. Veligrotug met all primary and secondary endpoints, with a 56% proptosis responder rate and 32% diplopia resolution. BLA submission is planned for 2025, aiming to transform TED treatment. VRDN-003, a subcutaneous therapy, is also advancing with topline data expected in 2026.